reports
First Community Bankshares, Inc. Announces Special Dividend
First Community Bankshares, Inc. Announces Special Dividend BLUEFIELD, Va., Dec. 16, 2025 (GLOBE NEWSWIRE) -- First Community Bankshares, Inc. (NASDAQ: FCBC) () (the “Company”) today reported its Board of Directors declared a special cash dividend to common shareholders of $1.00 per common share. The Company’s capital management plan and philosophy require the maintenance of a strong capital base from which to grow and serve customers. If current earnings are not needed to increase the capital base to fund growth in core operations or other uses, the capital management plan directs thos...
Atlanticus Refinances Securitization Facility
Atlanticus Refinances Securitization Facility ATLANTA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that on December 4, 2025, the Mercury subsidiaries of Atlanticus refinanced an existing $750 million term securitization. The new bonds are for three years, have more favorable structural elements, and achieved an immediate 200+ basis po...
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from...
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prog...
Atlanticus Announces Approval of Quarterly Preferred Stock Dividend
Atlanticus Announces Approval of Quarterly Preferred Stock Dividend ATLANTA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we” or “our”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that its Board of Directors approved a quarterly dividend of $0.476563 per share to Series B Cumulative Perpetual Preferred shareholders. The cash dividend will be paid on or about December 15, 2025 to holders of...
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and ...
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 20...
Atlanticus Reports Third Quarter 2025 Financial Results
Atlanticus Reports Third Quarter 2025 Financial Results CONTINUED GROWTH AND TRANSFORMATIONAL ACQUISITION RESULT IN EXPANSION TO OVER 5.7 MILLION CONSUMERS(1) SERVED AND $6.6 BILLION IN MANAGED RECEIVABLES(2) ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the third quarter ended September 30, 2025. ...
Royce Micro-Cap Trust Inc: 1 director
A director at Royce Micro-Cap Trust Inc sold 200,000 shares at 10.270USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Prelude Therapeutics Announces Strategic Business Update
Prelude Therapeutics Announces Strategic Business Update Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially into the third quarter of 2028 if Incyt...
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte ...
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milesto...
Prelude Therapeutics Announces Publication of Abstracts for Presentati...
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral presentation at the American Society of Hematology (ASH) 67th Annu...
First Community Bankshares, Inc. Announces Third Quarter 2025 Results ...
First Community Bankshares, Inc. Announces Third Quarter 2025 Results and Quarterly Cash Dividend BLUEFIELD, Va., Oct. 28, 2025 (GLOBE NEWSWIRE) -- First Community Bankshares, Inc. (NASDAQ: FCBC) () (the “Company”) today reported its unaudited results of operations and other financial information for the quarter ended September 30, 2025. The Company reported net income of $12.27 million, or $0.67 per diluted common share, for the quarter ended September 30, 2025. Net income for the nine months ended September 30, 2025, was $36.33 million or $1.97 per diluted common share. The Company...
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA...
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. “Katina brings to Prelude an...
Atlanticus Announces Acquisition of Mercury Financial LLC
Atlanticus Announces Acquisition of Mercury Financial LLC Adds $3.2 billion of credit card receivables to Atlanticus’ general purpose credit card segmentExpands Atlanticus’ product offering and capabilities into the much larger near-prime consumer segmentBrings together two platforms that share a relentless focus on meeting the needs of the financially underserved ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus”, the “Company”, “we”, “our” or “us”), announced today that it has acquired Mercury Financial LLC (“Mercury”). Mercury is a...
Atlanticus Announces Approval of Quarterly Preferred Stock Dividend
Atlanticus Announces Approval of Quarterly Preferred Stock Dividend ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we” or “our”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that its Board of Directors approved a quarterly dividend of $0.476563 per share to Series B Cumulative Perpetual Preferred shareholders. The cash dividend will be paid on or about September 15, 2025 to holders o...
Atlanticus Holdings Corporation Announces Pricing of $400 million Seni...
Atlanticus Holdings Corporation Announces Pricing of $400 million Senior Notes Offering ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we” or “our”) today announced that it has successfully priced an offering of $400,000,000 aggregate principal amount of 9.750% Senior Notes due 2030 (the “Notes”) to be issued by the Company and guaranteed by certain of its domestic subsidiaries. The Notes are expected to be issued on August 20, 2025, subject to the satisfaction or waiver of customary closing conditions. The Compa...
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and...
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development candidate for its oral KAT6A degrader program and remains on track to file an IND in the first half o...
Atlanticus Holdings Corporation Announces Offering of Senior Notes
Atlanticus Holdings Corporation Announces Offering of Senior Notes ATLANTA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we” or “our”) today announced an offering of $400,000,000 aggregate principal amount of Senior Notes due 2030 (the “Notes”) to be issued by the Company and guaranteed by certain of its domestic subsidiaries. The Company intends to use the net proceeds from the offering of the Notes (i) to repay amounts outstanding under its recourse warehouse facilities, (ii) for general corporate purposes, including to...
Atlanticus Reports Second Quarter 2025 Financial Results
Atlanticus Reports Second Quarter 2025 Financial Results Second Quarter 2025 net margin growth of 35.8% over prior year, with 4.0 million accounts served (1) ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the second quarter ended June 30, 2025. An accompanying earnings presentation is available in the I...
- Jonathan Moreland
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PRGS PROGRESS SOFTWARE CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CTAS CINTAS CORPORATION
CIVB CIVISTA BANCSHARES
MEDP MEDPACE HOLDINGS INC.
DYN DYNEGY INC.
PETS PETMED EXPRESS INC.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
PGC BRIDGEWATER BANCSHARES
LOOP PEAPACK-GLADSTONE FINANCIAL CORP.
CHMG LOOP INDUSTRIES
A2JHXF CHEMUNG FINANCIAL CORP.
FVCB CEVA LOGISTICS AG
FGBI FVCBANKCORP
REZI FIRST GUARANTY BANCSHARES
GRX RESIDEO TECHNOLOGIES
PCB INC.
FRHC THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV PACIFIC CITY FINANCIAL CORP
KYMR FREEDOM HOLDING CORP
DMAC COMMUNITY BANCORP INC. VT
NSPR KYMERA THERAPEUTICS
BRCC DIAMEDICA THERAPEUTICS INC.
BPRN INSPIREMD INC
STRW BRC INC
PMNT BANK OF PRINCETON
NYC STRAWBERRY FIELDS REIT INC.
GF PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
FGEN INC.
BMNR THE NEW GERMANY FUND
NEGG INC.
LIONSGATE STUDIOS CORP
FIBROGEN INC.
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.